On August 1st, 2022, China Medico Corporation's Cohesion Meeting of Places of Production in 2022 was held in Tianjin.
Over 100 people attended the meeting including executive management, leaders and collegues of relevant departments of China Medico Corporation, relevant leaders from Tsumura & Co., Ping'an Tsumura & Co., Shenzhen Tsummura & Co. and Pingmura Medico Corporation, clients from Shanghai Medicinal Materials Company as well as representatives from 55 domestic companies of places of production.
Chen Yanguo, deputy general manager of China Medico Corporation, delivered a speech and sent a warm welcome to representatives from companies of places of production who attened the meeting. He also made a report on some aspects such as China Medico Corporation's business performance, the third phase of factory construction, future goals and so on.
Hirate Takemi, minister of crude drug central department, made a speech through online video and expressed thankfulness to the places of production companies which showed lone-term cooperation and support to Tsumura's business.
At the meeting, Mr. Hirate gave a detailed introduction on Tsumura Group's settlement of 2021, results review of stable supply, Tsumura's vision of sustainable development, Tsumura's long-term operation vision of 2031 "Care for Health, accompany for a lifetime", the vision and strategy of crude drug central department in 2031, etc.
Watanabe Yoshiharu, deputy general manager of China Medico Corporation made an introduction about the business vision in China and three major business platforms of preparations, crude drugs and research. He emphasized that every place of production company should consolidate upstream work and truly achieve a shared and win-win situation.
Kondou Kenji, minister of production management department, elaborated the advantages and the characteristic fetures of GACP and at the same time made elaborted illustration about goals, vision and management style of GACP through online vedio.
Ministers from planting management department, purchase department and quality management department respectively made their working reports and gave special trainings on related professional questions.
Zhang Naiwu, minister of planting management department of China Medico Corporation, made a report on GACP management.
Zhang Xu, minister of quality management department of China Medico Corporation, made a report on crude drug quality in 2021 and shared information about fresh cutting processing in places of production.
Yao Xionghui, minister of purchase department of China Medico Corporation, made a report on the vocational work.
During the discussion and communication session, everyone spoke freely. Representatives from companies of places of production raised questions about planting in place of production, storage processing and quality management, etc. Leaders of China Medico Corporation gave elaborated answers and provided guidance.
At the end of the meeting, Li Gang, general manager of China Medico Corporation, made a summary statement. Mr. Li Gang expressed gratefulness to representatives from places of production companies despite the rise-and-fall epidemic environment. Mr. Li indicated that China Medico Corporation still got excellent achievement despite the ordeal brought by the impact of the epidemic during the past year. He said that the company couldn't get the achievement without all the places of production companies which stood together through storm and stress with China Medico Corporation and gave support to it.
Mr. Li pointed out that China Medico Corporation regards source management as core value all the time. He said it was one of the core points to figure out how to make source work and bases work solider and deeper. Mr. Li emphasized that crude drugs supply chain revolution and creation should start with planting and harvesting, preliminary working, mechanisation and manpower economization. The policy of fresh cutting processing and the long-term system of Tsumura Group should be taken good advantege of and a solid job at the front end should be done to achieve cost decreasing and benefit increasing under the premise of ensuring the quality of drugs.